{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:48:21Z","timestamp":1785919701506,"version":"3.56.0"},"reference-count":76,"publisher":"Informa UK Limited","issue":"18","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,7,27]]},"DOI":"10.1080\/14796694.2026.2700028","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:39:18Z","timestamp":1783525158000},"page":"2131-2142","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3011-915X","authenticated-orcid":false,"given":"Marina","family":"Samuel","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus S.","family":"Flores","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Lowy","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Rogers","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1208-9260","authenticated-orcid":false,"given":"Zachary M.","family":"Avigan","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2939-4385","authenticated-orcid":false,"given":"Mohammad A.","family":"Rattu","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"e_1_3_5_4_1","unstructured":"Cancer Stat Facts: Myeloma [Internet]. NCI surveillance epidemiology and end results (SEER) program. [cited 2026 Mar 9]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2026.0001"},{"key":"e_1_3_5_6_1","unstructured":"BLENREP (belantamab mafodotin-blmf). Prescribing information. GlaxoSmithKline LLC; 2025 [cited 2026 Mar 9]. Available from: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Blenrep\/pdf\/BLENREP-PI-MG.PDF"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01191-8"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01139-y"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2303379"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101342"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025030525"},{"key":"e_1_3_5_17_1","unstructured":"ELREXFIO (elranatamab-bcmm). Prescribing information. Pfizer Inc.; 2026 [cited 2026 Mar 9]. Available from: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19669"},{"key":"e_1_3_5_18_1","unstructured":"TECVALI (teclistamab-cqyv). Prescribing information. Janssen Biotech Inc.; 2025 [cited 2026 Mar 9]. Available from: https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/TECVAYLI-pi.pdf"},{"key":"e_1_3_5_19_1","unstructured":"LYNOZYFIC (linvoseltamab-gcpt). Prescribing information. Regeneron Pharmaceuticals Inc.; 2025 Jul [cited 2026 Mar 9]. Available from: https:\/\/www.regeneron.com\/downloads\/lynozyfic_fpi.pdf"},{"key":"e_1_3_5_20_1","unstructured":"TALVEY (talquetamab-tgvs). Prescribing information. Janssen Biotech Inc.; 2025 [cited 2026 Mar 9]. Available from: https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/TALVEY-pi.pdf"},{"issue":"2","key":"e_1_3_5_21_1","first-page":"S413","article-title":"Real-world incidence of infections in BCMA-targeting bi-specific antibodies in relapsed\/refractory multiple myeloma","volume":"31","author":"Snyder J","year":"2023","unstructured":"Snyder J, McElwee J, Hill H, et al. Real-world incidence of infections in BCMA-targeting bi-specific antibodies in relapsed\/refractory multiple myeloma. Transpl Cell Ther. 2023;31(2):S413\u2013S414.","journal-title":"Transpl Cell Ther"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011658"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029572"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70260"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029773"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117252"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0035"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14145"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-025-01508-1"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/md18120619"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03758-9"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26823"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288203"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023557"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12660"},{"key":"e_1_3_5_37_1","unstructured":"Drug development and drug interactions | Table of substrates inhibitors and inducers [Internet]. US Food and Drug Administration; 2023 [cited 2026 Mar 9]. Available from: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0196-6"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34987"},{"key":"e_1_3_5_42_1","unstructured":"FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma [Internet]. US Food and Drug Administration; 2024 [cited 2026 Mar 9]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00243-0"},{"key":"e_1_3_5_44_1","unstructured":"GSK provides an update on blenrep (belantamab mafodotin-blmf) US marketing authorisation. Press release. GlaxoSmithKline; 2022 [cited 2026 Mar 9]. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-update-on-blenrep-us-marketing-authorisation\/"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00330-4"},{"key":"e_1_3_5_47_1","unstructured":"FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma. US Food and Drug Administration; 2025 [cited 2026 Mar 9].Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belantamab-mafodotin-blmf-relapsed-or-refractory-multiple-myeloma"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-2264"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284347"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031629"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025019050"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281772"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-022-00212-5"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18479"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411829"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00592-3"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1026251"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112964"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.08.003"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14222"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.907"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100103"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26728"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae177"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678634"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02703-y"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173074"},{"key":"e_1_3_5_69_1","unstructured":"BLENREP (belantamab mafodotin-blmf) REMS (risk Evaluation and Mitigation Strategy). GlaxoSmithKline LLC; [cited 2026 Mar 9]. Available from: https:\/\/www.blenreprems.com\/"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70015"},{"key":"e_1_3_5_71_1","unstructured":"BLENREP (belantamab mafodotin-blmf). Prescribing information. GlaxoSmithKline LLC; 2026. [cited 2025 Feb 9]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/blenrep-epar-product-information_en.pdf"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025945"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015526"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01365"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01081-z"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023616"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01314-9"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-026-01477-z"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2700028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2026.2700028","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2700028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:12:25Z","timestamp":1785917545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2026.2700028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":76,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,7,27]]}},"alternative-id":["10.1080\/14796694.2026.2700028"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2026.2700028","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}